Prosecution Insights
Last updated: April 19, 2026

Examiner: SPENCE, JENNIFER SUZANNE

Tech Center 1600 • Art Units: 1631 1633 1634 1651

This examiner grants 67% of resolved cases

Performance Statistics

67.0%
Allow Rate
+7.0% vs TC avg
169
Total Applications
+45.1%
Interview Lift
1401
Avg Prosecution Days
Based on 106 resolved cases, 2023–2026

Rejection Statute Breakdown

4.6%
§101 Eligibility
16.0%
§102 Novelty
42.1%
§103 Obviousness
23.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18025719 DUAL-AAV VECTOR DELIVERY OF PCDH15 AND USES THEREOF Final Rejection President and Fellows of Harvard College
17618080 METHOD FOR PRODUCING RENAL INTERSTITIAL CELL Final Rejection Takeda Pharmaceutical Company Limited
17640281 CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18266689 DIFFUSION GRADIENT ASSAY FOR ANTI-CD3-CONTAINING MOLECULES Non-Final OA AMGEN INC.
16906937 METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION Final Rejection Hoffmann-La Roche Inc.
18017139 M13 BACTERIOPHAGE WITH A HIGH CYSTEINE CONTENT AND GENETICALLY ENGINEERABLE HYDROGELS Non-Final OA Massachusetts Institute of Technology
18182377 METHOD FOR BUILDING CO-CULTURE MODEL FOR CACO-2/RAW-264.7 CELLS INDUCED BY LIPOPOLYSACCHARIDES AND APPLICATION OF CO-CULTURE MODEL Final Rejection ZHEJIANG UNIVERSITY OF TECHNOLOGY
19206692 METHODS, APPARATUSES AND SYSTEMS FOR INSTILLING STEM CELLS AND PHARMACEUTICALS INTO THE HUMAN VENTRICULAR SYSTEM Final Rejection Regeneration Biomedical, Inc.
17344125 METHODS, APPARATUSES AND SYSTEMS FOR INSTILLING STEM CELLS AND PHARMACEUTICALS INTO THE HUMAN VENTRICULAR SYSTEM Non-Final OA Regeneration Biomedical, Inc.
17756116 LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
19182523 METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF Non-Final OA FUJIFILM Cellular Dynamics, Inc.
18042037 CONSUMABLE TISSUE-LIKE STRUCTURE GENERATED WITH MUSCLE CELLS GROWN ON EDIBLE HOLLOW FIBERS Non-Final OA Merck Patent GmbH
18662599 ALIGNMENT OF CELLS IN ENGINEERED TISSUES Non-Final OA Regents of the University of Minnesota
18178736 METHODS AND MICROFLUIDIC DEVICE FOR PRODUCING EXTRACELLULAR VESICLES Non-Final OA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
17276213 VECTORS EXPRESSING COLOR AND SELECTABLE MARKERS Final Rejection THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
18249339 AN ADHERENT CELL CULTURE METHOD FOR GENERATING TIGHT JUNCTION BETWEEN CELLS AND ITS PRODUCT APPLICATION Non-Final OA ZHEJIANG UNIVERSITY
18955455 METHODS OF RECOMBINANT ADENO-ASSOCIATED VIRUS KIDNEY ADMINISTRATION Non-Final OA ASKBIO INC.
17798719 CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF Final Rejection Sichuan University
18196538 MIR-375- AND MIR-1-REGULATED COXSACKIEVIRUS B3 HAS NO PANCREAS AND HEART TOXICITY BUT STRONG ANTITUMOR EFFICIENCY IN COLORECTAL CARCINOMAS Non-Final OA Technische Universität Berlin
17272126 ENGINEERED REGULATORY T CELL Non-Final OA KING'S COLLEGE LONDON
17354281 METHODS AND COMPOSITIONS FOR CULTIVATING PLURIPOTENT CELL SUSPENSIONS Non-Final OA Life Technologies Corporation
17614934 THERAPEUTIC B-CELLS ENGINEERED TO EXPRESS BISPECIFIC T CELL ENGAGER ANTIBODIES Final Rejection H. Lee Moffitt Cancer Center and Research Institute, Inc.
18046930 METHOD FOR REJUVENATING GLIAL PROGENITOR CELLS AND REJUVENATED GLIAL PROGENITOR CELLS PER SE Final Rejection UNIVERSITY OF ROCHESTER
16482420 ENGINEERING BLOOD VESSEL CELLS FOR TRANSPLANTATION Final Rejection CORNELL UNIVERSITY
18673148 FUNCTIONALIZED WELL PLATE, METHODS OF PREPARATION AND USE THEREOF Non-Final OA BRUKER CELLULAR ANALYSIS, INC.
18425997 SDC-2 EXOSOME COMPOSITIONS AND METHODS OF ISOLATION AND USE Non-Final OA Orbsen Therapeutics Limited
18397846 GENETICALLY MODIFIED MOUSE, METHODS FOR PRODUCING THE SAME, AND USES THEREOF Non-Final OA MacKay Memorial Hospital
18290183 Antisense Oligomer Non-Final OA NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
18571292 METHOD FOR PURIFICATION OF GMP-GRADE RETROVIRAL VECTOR AND APPLICATION THEREOF Non-Final OA CARBIOGENE THERAPEUTICS CO., LTD.
17757069 MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES Final Rejection EDITAS MEDICINE, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month